Abstract
The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30–April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote “Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy.” (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that the desired renaissance of solid basic HS research is progressing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as “the only inflammatory skin disease than can be healed”. This anniversary article of 43 research-performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future.
| Original language | English |
|---|---|
| Pages (from-to) | 1154-1170 |
| Number of pages | 17 |
| Journal | Experimental Dermatology |
| Volume | 29 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2020 |
Keywords
- acne inversa
- hair follicle
- hidradenitis suppurativa
- inflammatory skin diseases
- pathogenesis
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Dermatology
Fingerprint
Dive into the research topics of 'What causes hidradenitis suppurativa ?—15 years after'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
What causes hidradenitis suppurativa ?—15 years after. / Zouboulis, Christos C.; Benhadou, Farida; Byrd, Angel S.; Chandran, Nisha S.; Giamarellos-Bourboulis, Evangelos J.; Fabbrocini, Gabriella; Frew, John W.; Fujita, Hideki; González-López, Marcos A.; Guillem, Philippe; Gulliver, Wayne P.F.; Hamzavi, Iltefat; Hayran, Yildiz; Hórvath, Barbara; Hüe, Sophie; Hunger, Robert E.; Ingram, John R.; Jemec, Gregor B.E.; Ju, Qiang; Kimball, Alexa B.; Kirby, Joslyn S.; Konstantinou, Maria P.; Lowes, Michelle A.; MacLeod, Amanda S.; Martorell, Antonio; Marzano, Angelo V.; Matusiak, Łukasz; Nassif, Aude; Nikiphorou, Elena; Nikolakis, Georgios; Nogueira da Costa, André; Okun, Martin M.; Orenstein, Lauren A.V.; Pascual, José Carlos; Paus, Ralf; Perin, Benjamin; Prens, Errol P.; Röhn, Till A.; Szegedi, Andrea; Szepietowski, Jacek C.; Tzellos, Thrasyvoulos; Wang, Baoxi; van der Zee, Hessel H.
In: Experimental Dermatology, Vol. 29, No. 12, 12.2020, p. 1154-1170.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - What causes hidradenitis suppurativa ?—15 years after
AU - Zouboulis, Christos C.
AU - Benhadou, Farida
AU - Byrd, Angel S.
AU - Chandran, Nisha S.
AU - Giamarellos-Bourboulis, Evangelos J.
AU - Fabbrocini, Gabriella
AU - Frew, John W.
AU - Fujita, Hideki
AU - González-López, Marcos A.
AU - Guillem, Philippe
AU - Gulliver, Wayne P.F.
AU - Hamzavi, Iltefat
AU - Hayran, Yildiz
AU - Hórvath, Barbara
AU - Hüe, Sophie
AU - Hunger, Robert E.
AU - Ingram, John R.
AU - Jemec, Gregor B.E.
AU - Ju, Qiang
AU - Kimball, Alexa B.
AU - Kirby, Joslyn S.
AU - Konstantinou, Maria P.
AU - Lowes, Michelle A.
AU - MacLeod, Amanda S.
AU - Martorell, Antonio
AU - Marzano, Angelo V.
AU - Matusiak, Łukasz
AU - Nassif, Aude
AU - Nikiphorou, Elena
AU - Nikolakis, Georgios
AU - Nogueira da Costa, André
AU - Okun, Martin M.
AU - Orenstein, Lauren A.V.
AU - Pascual, José Carlos
AU - Paus, Ralf
AU - Perin, Benjamin
AU - Prens, Errol P.
AU - Röhn, Till A.
AU - Szegedi, Andrea
AU - Szepietowski, Jacek C.
AU - Tzellos, Thrasyvoulos
AU - Wang, Baoxi
AU - van der Zee, Hessel H.
N1 - Funding Information: All authors declare that none of the mentioned conflicts of interest had any influence to this manuscript. CCZ has received thematically relevant honoraria from AbbVie as advisor and conference speaker and from Idorsia, Incyte, Inflarx, Janssen‐Cilag, Novartis, Regeneron and UCB as advisor. His departments have received grants from AbbVie, AOTI, Astra Zeneca, Galderma, Inflarx, Naos‐Bioderma, Novartis, PPM and UCB for his participation as clinical investigator. NSC has received fees from AbbVie, Johnson & Johnson and Sanofi for participation in advisory boards, investigator fees for clinical trials from AbbVie, Novartis and Sanofi and speaker honoraria from Galderma, Johnson & Johnson and LEO. EJG‐B has received honoraria from Abbott, Angelini, bioMérieux, InflaRx, MSD and XBiotech; independent educational grants from AbbVie, Abbott, Astellas, AxisShield, bioMérieux, InflaRx, ThermoFisher Brahms and XBiotech; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie‐Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). JWF was supported in part by a grant (no. UL1 TR001866) from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) Program. HF has received honoraria for speaker and/or consultancy from AbbVie, Boehringer‐Ingelheim, Celgene, Eisai, Eli Lilly, Novartis, Janssen‐Cilag, Marho, Sanofi, Taiho, Tanabe‐Mitubishi and UCB. PG received honoraria from AbbVie and Novartis as a consultant and provided lectures for AbbVie, Brothier, Cicaplus, Coloplast, Inresa and Novartis. MAG‐L reports consultation fees/participation in company‐sponsored speaker's bureau from Abbvie. WPFG reports grants and research support by AbbVie, Amgen, Eli Lilly, Novartis, Pfizer; honoraria for invited talks and consultation by AbbVie, Actelion, Amgen, Arylide, Bausch Health, Boehringer, Celgene, Cipher, Eli lilly, Galderma, Janssen, LEO, Novartis, PeerVoice, Pfizer, Sanofi, Tribute, UCB, Valeant; and study fees from clinical trials by AbbVie, Asana, Astellas, Boehringer‐Ingleheim, Celgene, Corrona/National Psoriasis Foundation, Devonian, Eli Lilly, Galapagos, Galderma, Janssen, LEO, Novartis, Pfizer, Regeneron, UCB. IH reports consultation fees/participation in advisory board of AbbVie; grant/research funding from AbbVie, Allergan, Bayer, Bristol‐Myers Squibb, Clinuvel, Estee Lauder, Ferndale, Galderma, GE, Incyte, Janssen‐Cilag, Johnson & Johnson, Lenicura, L’Oreal, LP, Merck, PCORI, Pfizer, Unigen; and consulting fees from Incyte. BH reports fees from AbbVie, Akari, Celgene, Janssen‐Cilag, Novartis and UCB for advisory boards, AbbVie, Janssen‐Cilag, LEO, Novartis, Philips, Roche, Regeneron, Sanofi and UCB for consultations; AbbVie, Akari, Celgene, Janssen‐Cilag, Novartis and Solenne for investigator initiative studies, and AbbVie and Janssen‐Cilag for educational grants, which fees were payed to the institution. REH has received thematically relevant honoraria from AbbVie and Novartis. JRI is a consultant to Kymera Therapeutics, Novartis, UCB and Viela Bio, and has received a speaker's honorarium from UCB and travel expenses from AbbVie and UCB. GBEJ has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Kymera Therapeutics, LEO, Novartis and UCB for participation on advisory boards, and grants from Abbvie, Astra‐Zeneca, Inflarx, Janssen‐Cilag, LEO, Novartis, Regeneron and Sanofi for participation as an investigator, and received speaker honoraria from AbbVie, Boehringer‐Ingelheim, Galderma and Novartis. He has also received unrestricted departmental grants from LEO and Novartis. JSK reports fees from AbbVie, Incyte, Viela Bio for advisory boards, AbbVie, ChemoCentryx, Incyte, Novartis, Bayer, UCB for consultations and AbbVie as speaker. MPK is investigator for Abbvie, Boehringer‐Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB and has received honoraria from AbbVie, Eli Lilly, LEO and Novartis. ABK is consultant and Investigator for Abbvie, Eli Lilly, Janssen‐Cilag, Novartis, Pfizer and UCB, consultant for Kymera Therapeutics, investigator for ChemoCentryx and Board of Directors for Almirall and received fellowship funding from AbbVie and Janssen‐Cilag. MAL has served on the advisory boards for Abbvie, Janssen‐Cilag, and Viela Bio, and consulted for Almirall, BSN, Incyte, Janssen‐Cilag, Kymera Therapeutics, and XBiotech. ASM is supported by funds from the National Institute of Health (R01AI139207) and the Department of Dermatology of Duke University. She reports fees from Silab (consultancy, grant, speaker honorarium). Silab had no involvement, influence or decision on the content of this manuscript or the decision to publish. ASM also reports fees from the LEO Foundation (Scientific Evaluation Committee) and her spouse is employed at Precision Biosciences and holds stock and stock options in this company. AM has served as a consultant for and received speaker fees from AbbVie, Celgene, Eli Lilly, Isdin, Janssen‐Cilag, LEO, MSD, Novartis, Pfizer and UCB. ŁM reports personal fees from AbbVie, Amgen, Galapagos, InflaRx, Janssen‐Cilag, LEO, Menlo, Novartis, Pfizer, Pierre Fabre, Regeneron, Trevi and UCB. ANdC is an AstraZeneca employee and owns AstraZeneca stocks. AstraZeneca had no involvement, influence or decision on the content of this manuscript. LAVO is supported by funds from the National Institute of Health (K12D085850). She is an investigator for ChemoCentryx. JCP reports honoraria from AbbVie for participation on advisory boards. MMO received honoraria from AbbVie for speaker services, and from AbbVie, Azora, Boehringer Ingelheim, Gilead, GSK, Incyte, Innovaderm, InflaRx, Genentech, Pfizer, Regeneron, Seattle Genetics for consultant services. RP is founder and CEO of Monasterium Laboratory Skin & Hair Research Solutions. EPP received honoraria from AbbVie, Amgen, Celgene, Galderma, Janssen‐Cilag, Novartis and Pfizer for participation as a speaker and serving on advisory boards and investigator‐initiated grants (paid to the Erasmus MC) from AbbVie, AstraZeneca, Janssen‐Cilag and Pfizer. TAR is associated with Novartis Institutes for Biomedical Research and is employee of Novartis Pharma AG. JCS reports personal fees from AbbVie, Amgen, Galapagos, InflaRx, Janssen‐Cilag, LEO, Menlo, Novartis, Pierre Fabre, Regeneron, Sandoz, Sanofi, Sienna, Trevi and UCB. AS has received thematically relevant honoraria from AbbVie, Eli Lilly, Janssen‐Cilag, LEO, Novartis, Sanofi and UCB and was supported by the Hungarian National Research, Development and Innovation Fund (K‐128250). TT reports fees from AbbVie, UCB and Sanofi (consultancy, speaker honorarium). HHvdZ reports fees from AbbVie and InflaRx. FB, ASB, GF, YH, SH, QJ, MPK, AVM, AN, EN, GN, BP and BW declare no conflict of interest. Publisher Copyright: © 2020 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30–April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote “Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy.” (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that the desired renaissance of solid basic HS research is progressing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as “the only inflammatory skin disease than can be healed”. This anniversary article of 43 research-performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future.
AB - The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30–April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote “Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy.” (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that the desired renaissance of solid basic HS research is progressing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as “the only inflammatory skin disease than can be healed”. This anniversary article of 43 research-performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future.
KW - acne inversa
KW - hair follicle
KW - hidradenitis suppurativa
KW - inflammatory skin diseases
KW - pathogenesis
UR - http://www.scopus.com/inward/record.url?scp=85097149336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097149336&partnerID=8YFLogxK
U2 - 10.1111/exd.14214
DO - 10.1111/exd.14214
M3 - Review article
C2 - 33058306
AN - SCOPUS:85097149336
VL - 29
SP - 1154
EP - 1170
JO - Experimental Dermatology
JF - Experimental Dermatology
SN - 0906-6705
IS - 12
ER -